Whilst there have not been any clinical trials specifically on the effects of Nrf2 activation on liver disease, a number of studies have investigated the effects of Nrf2 activators in rodent models of NAFLD and NASH (Table 2). The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatohepatitis.